Supernus Pharmaceuticals, Inc.
SUPNHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jun 3, 2026
Scan Results
Daily timeframeSupernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United. Valued at $2.56B, SUPN is a mid-cap name in its sector. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
Market Cap
$2.56B
Beta
0.57
P/E (TTM)
—
P/E (Fwd)
10.09
EPS (TTM)
$-0.51
EPS (Fwd)
$4.37
ROE
-2.8%
ROA
1.1%
Cash
$384.2M
Total Debt
$40.9M
Free CF
$132.6M
52W Change
36.4%
Annual Financials
Cash vs Debt
With $384.2M in cash and $40.9M in debt, SUPN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $132.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -2.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.1% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $667.2M (2022) to $719.0M (2025).
With a beta below 0.7, Supernus Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, SUPN has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Supernus Pharmaceuticals, Inc.'s trajectory.